The dosage used in RASopathies is typically lower than in oncology, which can be explained by the fact that germline mutations in RASopathies often display a lower gain-of-function compared to somatic cancer mutations where higher ERK phosphorylation levels determine stronger hyperactivation of the cascade, thus require higher MEK inhibitor dosing (6, 7, 9, 37, 42, 51). Here, MAP2K7 is linked to RASopathy.